The 2021 edition of the European Stroke Organization (ESO) guideline for acute treatment recommends considering thrombolysis for patients on factor Xa inhibitors such as apixaban and rivaroxaban when anti-FXa activity (AFXa) is <0.5 × 103 IU/L, presumably representing an activity corresponding to low drug concentrations [6]. This evidence concerns the gene F10 and Stroke.